Mice Model Market Size, Share, and Industry Analysis By Model Type (Inbred Mice, Hybrid Mice, Immunodeficient Mice, and Others (Oncology Mice, Humanized Mice, Transgenic Mice)), By Services (Breeding Services, Colony Management, Model Generation, and Others), By Therapeutic Area (Oncology, Cardiology, Metabolic Disease, and Others (Neurology, Immunology)), and By End User (Pharmaceutical & Biotechnology Companies, Research Institutes, and Others), and Regional Forecast, 2026-2034

The global mice model market size was valued at USD 1.71 billion in 2025. The market is projected to grow from USD 1.88 billion in 2026 to USD 4.07 billion by 2034, exhibiting a CAGR of 10.13% during the forecast period.

The global mice model market is experiencing substantial expansion driven by the rapid development in genetic engineering technologies, such as CRISPR, which have transformed the production of disease-specific mouse models for study and pharmaceutical purposes. The rising incidence of chronic disease, including cancer and heart conditions, has increased the need for individualized therapies, therefore driving further market expansion. Furthermore, the driving mouse models to become a critical instrument in finding new treatments are the increasing number of pre-clinical trials and ongoing investigations by biopharmaceutical and pharmaceutical businesses. Expanding use of mouse models and innovation in model development are being driven by strategic alliances among major industry participants, as developing areas increase investment in medical infrastructure.

• According to the National Institutes of Health, in 2023, 186000 genetically engineered mice were used in NIH-funded studies

Mice Model Market Driver

Advancements in Genetic Engineering Technologies, Rising Demand for Personalized Medicine, and Increasing Preclinical Trials and R&D Efforts to Foster Market Growth

The development of CRISPR/Cas9 technology has greatly advance the production of genetically modified mouse models, hence providing more accurate illnesses simulations. More accurate replication of human diseases will help to make biomedical studies more applicable. Understanding disease processes and gene therapy depend on mouse models nowadays quite much.

Rising incidence of long-term illnesses such cancer has spurred the need for individualized medicine, which is largely based on mice models for development of treatments. These models support the testing of medicines specifically adapted to personal genetic profiles, therefore driving up consumer demand since more focused treatments are required.

Mice Model Market Restraint

Ethical Concerns and Regulatory Restrictions, Development of Alternative Testing Methods, and Genetic and Phenotypic Variability May Affect Market Expansion

Strict ethical standards and government regulations governing the use of animals in experiments can slow down mouse model research. Although intended to provide decent treatment, these standards may restrict the pace and range of research, especially in disciplines demanding extensive animal experimentation.

The increasing use of alternative approaches, including in vitro testing and computer modeling, challenges the conventional mouse model dependence. These other options promise quicker, less intrusive, and less costly research, thereby lowering the need for animal models.

In mouse models, genetic and phenotypic differences may complicate the attainment of consistency and reproducibility in studies. Different research results and therefore reliability and accuracy of experimental findings may be influenced by these variations, therefore complicating the application of mice models in research.

Mice Model Market Opportunity

Utilization of CRISPR in Biomedical Research, Expansion into Emerging Markets, and Collaborations and Partnerships to Offer New Market Avenues

The development of disease specific mouse models has been transformed by CRISPR technology in gene editing, therefore opening fresh possibilities for exact and effective research. The mice model industry's growth potential is greatly improved by this technology's power to make precise genetic alterations.

Significant growth chances for the acceptance of mice models come from developing areas with increasing investments in research and healthcare infrastructure. The need for dependable pre-clinical models, such mice models, is rising as these areas of the world become more focused on biomedical research.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Chronic Diseases and Research Demand, By Key Countries
• Market Trends in Mice Model Development Across Major Regions
• Major Market Drivers, Trends, and Investment Opportunities
• Business Strategies Adopted by Key Players and Key Industry Developments (Mergers, Acquisitions, Partnerships)
• Overview: Regulatory Scenario and Government Policies

Analysis by Model Type

By model type, the Mice Model market is divided into inbred mice, hybrid mice, immunodeficient mice, and others (oncology mice, humanized mice, transgenic mice)

Research depends on inbred mice for their uniformity and dependability in studies since they are genetically uniform and therefore popular. Particularly in genetic and drug studies, this model is most common in pre-clinical trials and keeps to see great growth given its proven use in several areas of research.

Created from crossing various inbred strains, hybrid mice provide genetic variation important for research on complex illnesses and immune responses. Increasing use in immunology and cancer research, and the capability to simulate more sophisticated human conditions are driving this segment at a strong pace.

Analysis by Services

By services, the Mice Model market is divided into breeding services, colony management, model generation, and others

For research uses, genetically consistent animals require essential breeding services in the mouse model industry. Demand for genetically engineered models and particular strain availability, essential for many disease studies, is driving this sector once upon a time.

Maintaining the health, genetics, and ideal environment of mouse colonies is the main issue addressed by colony management solutions. Particularly in big pre-clinical studies, this region is expanding notably thanks to demand for effective and legal genetics and maintenance systems.

Analysis by Therapeutic Area

By therapeutic area, the Mice Model market is divided into onoclogy, cardiology, metabolic disease, and others (neurology, immunology)

Since these models are essential for testing cancer treatments and grasping tumor biology, oncology remains a primary therapeutic field for the mice model sector. Rising numbers of cancer research programs and drug development efforts are driving the segment's notable expansion.

Mice models have a major part in researching cardiac disorders and evaluating cardiovascular therapies, in addition to being a difficult field of therapy in cardiology. Growing steadily, this component is driven by the increasing worldwide incidence of cardiovascular disorders and a need for accurate models to simulate human conditions.

Analysis by End-User

By end-user, the Mice Model market is divided into pharmaceutical & biotechnology companies, research institutes, and others

As they depend on these models for drug development, pre-clinical experiments, and therapeutic testing, pharmaceutical and biotechnology businesses represent a major end-user group in the mice model industry. The rising need for new medications and drug pipelines helps to power the significant growth of this sector.

Using mouse models for basic research, disease research, and experimental validations, research organizations are another important end user. With increasing government and corporate sector expenditure on scientific studies and academics driving demand for sophisticated research tools, including mice models, this sector is growing steadily.

Regional Analysis

Based on region, the Mice Model market has been studied across North America, South America, Europe, the Middle East & Africa, and the Asia Pacific

To gain extensive insights into the market, Download for Customization

North America’s, state-of-th-eart biomedical research facilities and significant financial support provide a solid basis for the widespread application of mice models in scientific research. Preclinical research requirements are pushed by top pharmaceutical and biotechnology businesses in the area, therefore driving market growth. Research facilities and high industry concentration together set North America as a major market for mice models.

Europe's strong biomedical research infrastructure, under girded by top universities and research groups, supports a great need for mouse models. European government funding and measures supporting research and development also help to drive the growth of the market, therefore Europe is a key participant in the international mice model business.

Particularly in China and India, the fast development of the pharmaceutical and biotechnology industries in Asia Pacific has really raised the need for mice models in experiments. The increasing attention on personalized medicine in the area, especially on tailored healthcare solutions, speeds up the use of specialized mice models and sets Asia Pacific up for significant market expansion.

Key Players Covered

The report includes the profiles of the following key players:

• Charles River Laboratories – U.S.
• Taconic Biosciences, Inc. – U.S.
• Cyagen – U.S.
• genOway – France
• The Jackson Laboratory – U.S.
• Creative Animodel – China
• Applied StemCell – U.S.
• Gubra – Denmark
• Biocytogen – China

Key Industry Players

• In December 2023, Biocytogen entered into a licensing agreement with Neurocrine Biosciences, granting the latter rights to selected antibodies for therapeutic product development, manufacturing, and commercialization globally.
• In November 2021, Inotiv, a leading contract research organization, completed the acquisition of Envigo, a provider of research models and services, enhancing Inotiv's product and service offerings in the mice model market.
• In February 2021, Charles River Laboratories announced the acquisition of Cognate BioServices, a cell and gene therapy contract development and manufacturing organization, to expand its capabilities in the mice model market and related research areas.